Continuing Education Information
© 2017 Harborside Press®
Genetic Counseling in Gynecologic Oncology:
What Advanced Practitioners Need to Know
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Release date: 10/17/2017
Expiration date: 10/16/2018
Estimated time to complete activity: 1.50 hours
|Annenberg Center for Health Sciences
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Journal of the Advanced Practitioner in Oncology
94 North Woodhull Road
Huntington, NY 11743
© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
Paula Anastasia, RN, MN, AOCN®, Cedars-Sinai Medical Center
Heather Hampel, MS, LGC, The Ohio State University Comprehensive Cancer Center
Brianna Hoffner, MSN, ANP-BC, AOCNP®, University of Colorado Cancer Center
Leigha Senter, MS, LGC, The Ohio State University Wexner Medical Center
Activity Rationale and Purpose
The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Genetic counseling for germline mutations and for somatic mutations have both grown exponentially in the last decades. Leading oncologists and genetics stakeholders strongly recommend that qualified oncology providers conduct predictive genetic testing. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.
The activity’s target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
After completing this educational activity, participants should be able to:
- Demonstrate increased understanding of the role genetic testing and counseling play in the oncology setting
- Discuss the difference in germline and somatic gene mutation and make appropriate recommendations for counseling.
- Identify appropriate key points in the patient/family history for genetic counseling referral and/or genetic testing
- Discuss the various patient communication tools to convey pertinent information on genetic testing and counseling.
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
In support of improving patient care, this activity has been planned and implemented by the Advanced Practitioner Society for Hematology and Oncology (APSHO) and the Society of Gynecologic Oncology (SGO). SGO is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SGO designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credit™, ANCC contact hours, or 0.15 ACPE CEU credits. Physicians, nurses, nurse practitioners, and pharmacists should only claim credit commensurate with the extent of their participation in the program.
American academy of physician assistants (AAPA)
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.50 hours of Category 1 credit for completing this activity.
Pharmacy UAN: 0594-0000-17-004-H01-P.
Start date: October 17, 2017; Expiration date: October 17, 2018.
Pharmacists will receive 0.15 amount of ACPE CEU credit upon completion of this activity.
The learner must submit their NABP ePID and DOB to the provider by after completing the online post test and evaluation.
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Society of Gynecologic Oncology identified and resolved all conflicts of interest through mechanisms included in the SGO’s Conflict of Interest Resolution Policy.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Paula Anastasia, RN, MN, AOCN®, has served on speakers bureaus for Clovis, Genentech, and Merck.
Heather Hampel, MS, LGC, has equity interests/stock options and has served on the advisory board for Genome Medical, has served on the advisory board for Invitae, has acted as a consultant for BeaconLBS, and has served as the PI of a research study that received donated genetic testing from Myriad Genetic Laboratories.
Brianna Hoffner, MSN, ANP-BC, AOCNP®, has served as a consultant for Abbott Laboratories, Lilly,
Leigha Senter, MS, LGC, has received consulting fees/honoraria from AstraZeneca, Clovis, and MyGene Counsel, and has served on speakers bureaus for FORCE, LBBC, and AstraZeneca.
Society of Gynecologic Oncology
Teri Jordan, CAE, CMP, has nothing to disclose.
Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Patricia McLafferty has nothing to disclose.
Larry Rosenberg has nothing to disclose.
Lynn Rubin has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Annie Yueh has nothing to disclose.
Moshe Ornstein, MD, MA, has nothing to disclose.
Nancy M. Nix, PharmD, BCPS, BCOP, has nothing to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of Society of Gynecologic Oncology, Advanced Practitioner Society for Hematology and Oncology (APHSO), Harborside Medical Education, and JADPRO educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online,
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.